Introduction/Background To review the surgical outcomes of cytoreductive surgery for ovarian cancer in a single institution.

Methodology we reviewed all patients with ovarian cancer who received a cytoreductive surgery between January 2005 and December 2018 at Hôtel-Dieu de France University Hospital, Lebanon.

Results 161 patients were included. Mean age at surgery was 54 years (range 16–83 years). Cytoreductive surgery was primary in 40% of cases. Surgical resection included bowel resection (48%), diaphragmatic peritoneal resection (25%) and splenectomy (15%). 89% of patients received a pelvic and para-aortic lymphadenectomy. Node involvement was noted in 48% of cases. No recurrence was seen in 56% of cases and the mean interval of recurrence was estimated at 21 months. Overall survival was estimated at 40 months (range 2–165 months). According to cox regression test, we found that survival is significantly correlated to age, menopausal status, lymph node status, number of positive lymph nodes and lymph node ratio (LNR) (p=0.009, p=0.004, p=0.001, p=0.002 and p=0.004 respectively). Patients with LNR ≤0.03 had a survival of 50 months vs. 27 months in patients with LNR >0.03. Mean survival was estimated at 51 months in patients with only one positive LN vs. 26 months in patients with more than one positive LN. Lymphadenectomy neither increased the postoperative complications nor the transfusion rate and was only associated with longer operative time (p=0.7, p=0.85 and p=0.000 respectively). No impact on survival was detected whether the patient benefited from an upfront surgery or an interval one post neoadjuvant chemotherapy: 36 months vs 30 months respectively, (p=0.39).

Conclusion Huge efforts including extensive cytoreductive surgeries are being performed at institutions in developing countries in order to improve survival and lower recurrence in ovarian cancer patients.

Disclosure Nothing to disclose.